ClinicalTrials.gg

Program

Diazepam

Also written as “diazepam nasal spray”, “NRL-1” and “Diazepam Nasal Spray [Valtoco]”.

Its studies are mostly in Epilepsy · Seizures · Drug Resistant Epilepsy, led by 4 companies.

Furthest: phase 3, since Aug 12, 20119 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acorda Therapeutics40 open or runningphase 2since Aug 12, 2011Aug 12, 2011none ahead
Neurelis30 open or runningphase 3since Mar 17, 2016Mar 17, 2016none ahead
Pfizer10 open or runningphase 3since Apr 27, 2006Apr 27, 2006none ahead
UCB10 open or runningphase 1since Jun 5, 2025Jun 5, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2006First study: phase 3 study in SeizuresNew to PfizerPfizer · NCT00319501 · 234 enrolled · United States
  2. Aug 12, 2011Acorda Therapeutics's first study: phase 2 study in EpilepsyNew to Acorda TherapeuticsAcorda Therapeutics · NCT01417078 · 31 enrolled · United States
  3. Dec 9, 2014Phase 2 study in EpilepsyAcorda Therapeutics · NCT02316847 · 126 enrolled · United States
  4. Jun 15, 2015Phase 2 study in Drug Resistant EpilepsyAcorda Therapeutics · NCT02474407 · 78 enrolled · United States
  5. Jan 22, 2016Phase 1 study in HealthyAcorda Therapeutics · NCT02663999 · 15 enrolled · United States
  6. Mar 17, 2016Neurelis's first study: phase 1 study in EpilepsyNew to NeurelisNeurelis · NCT02724423 · 57 enrolled · United States
  7. Mar 17, 2016Phase 3 study in SeizuresNeurelis · NCT02721069 · 175 enrolled · United States
  8. Sep 15, 2021Phase 2 study in EpilepsyNeurelis · NCT05076838 · 36 enrolled · United States
  9. Jun 5, 2025UCB's first study: phase 1 study in Healthy ParticipantsNew to UCBUCB · NCT07020988 · 55 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamrulePfizerphase 496
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
brexanoloneruleSupernus Pharmaceuticalsphase 414

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07020988Healthy Participants · United States1CompletedUCBJan 6, 202655
NCT05076838Epilepsy · United States2CompletedNeurelisMar 11, 202536
NCT02724423Epilepsy · United States1CompletedNeurelisApr 10, 201957
NCT02721069Seizures · United States3CompletedNeurelisJun 17, 2020175
NCT02663999Healthy · United States1CompletedAcorda TherapeuticsApr 201615
NCT02474407Drug Resistant Epilepsy · United States2TerminatedAcorda TherapeuticsMay 201678
NCT02316847Epilepsy · United States2TerminatedAcorda TherapeuticsJul 2016126
NCT01417078Epilepsy · United States2CompletedAcorda TherapeuticsFeb 201331
NCT00319501Seizures · United States3CompletedPfizerJul 2014234

How it is read

Names in the registry

  • “diazepam nasal spray”, 3 entries
  • “Diazepam”, 2 entries
  • “NRL-1”, 2 entries
  • “Diazepam Nasal Spray [Valtoco]”, 1 entry
  • “Vanquix Auto-Injector (Diazepam Injection)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.